Novo Nordisk Stock Surges on Promising Wegovy Pill Trial Results
Novo Nordisk shares climbed over 5% in pre-market trading after revealing its oral semaglutide weight-loss pill achieved nearly identical results to its injectable Wegovy treatment in a phase 3 trial. The Danish pharmaceutical giant's tablet version demonstrated 16.6% average body weight reduction, positioning it as a formidable competitor to Eli Lilly's injectable alternatives.
Market enthusiasm reflects the strategic importance of oral administration in the obesity treatment space. "This marks the first time we've seen comparable efficacy between oral and injectable formulations," noted Ludovic Helfgott, Novo's executive vice president. The development could significantly expand patient access and market penetration for weight-loss therapies.
